Seattle Genetics, Inc., a biotechnology company that specializes in the development and commercialization of novel antibody-based therapies for the treatment of cancer, has officially begun a Phase II clinical study designed to test ADCETRIS (brentuximab vedotin) as a treatment for systemic lupus erythematosus (SLE). This drug candidate is an antibody-drug conjugate (ADC) that…
Pediatric Rheumatology Fellow at Albert Einstein College of Medicine of Yeshiva University and Children’s Hospital at Montefiore, Dr. Tamar Rubinstein, recently received the Lupus Foundation of America’s third yearly Career Development Award. “Now, more than ever, it is essential that young, energetic investigators receive funding for vital lupus research,” said…
An abstract presented during the American Academy of Orthopaedic Surgeons Annual Meeting 2015 in Las Vegas, revealed that patients with systemic lupus erythematosus (SLE) who had undergone total hip arthroplasty (THA) were nearly five times more likely to experience post-operative complications when compared to patients with osteoarthritis. Dr. Mark P. Figgie from the Hospital…
The role of biofilms, until recently, had been studied mostly in reference to bacterial deposition, protection and antibiotic resistance acquired by groups of bacteria due to formation of these structures. However, recent studies by a group of researchers at Temple University School of Medicine (TUSM) have shown that bacterial communities…
In a recent study entitled “Autoimmune Disease in First-Degree Relatives and Spouses of Individuals With Celiac Disease” researchers show that first-degree relatives and spouses of individuals with celiac disease have an increased risk of suffering from other type of autoimmune diseases, such as systemic lupus erythematosus. The study…
Autoimmune diseases such as acute systemic lupus erythematosus (SLE) have characteristically high levels of autoantibodies in afflicted patients’ serum. These antibodies are produced by antibody-secreting cells (ASCs), which are a relatively unstudied population of cells. One research group from the Department of Medicine, Division of Rheumatology, at Emory University in…
In a new study entitled “T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection” researchers discovered how T-cell exhaustion can determine the outcome of autoimmune diseases, suggesting that therapeutics targeting the underlying mechanism of T-cell exhaustion can benefit patient outcomes in diseases like systemic lupus erythematosus. The…
In a new study entitled “Tumor necrosis factor-alpha single nucleotide polymorphisms in juvenile systemic lupus erythematosus” researchers investigated genetic variants, specifically those known as single nucleotide polymorphisms, within the gene tumor necrosis factor-alpha (TNF-a), a potent pro-inflammatory cytokine that was previously suggested to play a role in juvenile…
The Senate Appropriations Committee’s 2016 spending bill passed June 25 includes some good news for people with lupus. Sandra C. Raymond, President & CEO of the Lupus Foundation of America notes in a statement that the bill provides support for funding of valuable lupus research and education programs, and…
Dr. Christine A. Peschken from the University of Manitoba in Winnipeg presented data on lupus disease in a Canadian cohort of patients, during the 70th Annual Meeting of The Canadian Rheumatology Association (CRA) in Quebec, Canada. The poster was entitled “Residual Lupus Disease Activity in a…